Trial Outcomes & Findings for A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001) (NCT NCT01798849)

Last Updated: 2019-07-22

Results Overview

An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized. Adverse events were summarized by dose taken at the time of the event.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

25 participants

Primary outcome timeframe

up to 7 weeks

Results posted on

2019-07-22

Participant Flow

In Panels A and B, 8 healthy male participants alternately received single rising doses of MK-8892 or placebo.In Panel C, 8 mild to moderate hypertensive male participants received single rising doses of MK-8892 determined by results of Panels A and B or placebo. Each period in a panel was separated by a 7-day washout.

Participant milestones

Participant milestones
Measure	Panel A-Healthy Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-8892 0.5 mg, 2.0 mg, 6.0 mg, or 14 mg, and 2 participants received placebo. Dosing periods alternated with Panel B.	Panel B-Healthy Within each of the 4 rising dose treatment periods, 6 participants received a single dose of MK-8892 1.0 mg, 4.0 mg, 9.0 mg or 12 mg, and 2 participants received placebo. Dosing periods alternated with Panel A.	Panel C-Mild/Moderate Hypertension Within each of the 5 single dose treatment periods, 6 participants with mild to moderate hypertension received a single dose of MK-8892 0.5 mg, 1.0 mg, 2.0 mg or 6.0 mg, and 2 participants received placebo. Dosages were determined by the results of Panels A and B.
Overall Study STARTED	8	8	9
Overall Study COMPLETED	8	8	8
Overall Study NOT COMPLETED	0	0	1

Reasons for withdrawal

Reasons for withdrawal
Measure	Panel A-Healthy Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-8892 0.5 mg, 2.0 mg, 6.0 mg, or 14 mg, and 2 participants received placebo. Dosing periods alternated with Panel B.	Panel B-Healthy Within each of the 4 rising dose treatment periods, 6 participants received a single dose of MK-8892 1.0 mg, 4.0 mg, 9.0 mg or 12 mg, and 2 participants received placebo. Dosing periods alternated with Panel A.	Panel C-Mild/Moderate Hypertension Within each of the 5 single dose treatment periods, 6 participants with mild to moderate hypertension received a single dose of MK-8892 0.5 mg, 1.0 mg, 2.0 mg or 6.0 mg, and 2 participants received placebo. Dosages were determined by the results of Panels A and B.
Overall Study Physician Decision	0	0	1

Baseline Characteristics

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Panel A-Healthy n=8 Participants Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-8892 0.5 mg, 2.0 mg, 6.0 mg, or 14 mg, and 2 participants received placebo. Dosing periods alternated with Panel B.	Panel B-Healthy n=8 Participants Within each of the 4 rising dose treatment periods, 6 participants received a single dose of MK-8892 1.0 mg, 4.0 mg, 9.0 mg or 12 mg, and 2 participants received placebo. Dosing periods alternated with Panel A.	Panel C-Mild/Moderate Hypertension n=9 Participants Within each of the 5 single dose treatment periods, 6 participants with mild to moderate hypertension received a single dose of MK-8892 0.5 mg, 1.0 mg, 2.0 mg or 6.0 mg, and 2 participants received placebo. Dosages were determined by the results of Panels A and B.	Total n=25 Participants Total of all reporting groups
Age, Continuous	42.8 years STANDARD_DEVIATION 9.5 • n=5 Participants	37.1 years STANDARD_DEVIATION 15.1 • n=7 Participants	50.6 years STANDARD_DEVIATION 5.3 • n=5 Participants	43.8 years STANDARD_DEVIATION 11.6 • n=4 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Sex: Female, Male Male	8 Participants n=5 Participants	8 Participants n=7 Participants	9 Participants n=5 Participants	25 Participants n=4 Participants

PRIMARY outcome

Timeframe: up to 7 weeks

Population: All healthy participants (Panels A and B) who received at least 1 dose of the study drug. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 14.0 mg MK-8892	Placebo-Healthy n=16 Participants Single oral dose of placebo to match MK-8892
Percentage of Participants Who Report 1 or More Adverse Events (AEs)- Healthy Participants	50.0 Percentage of Participants	66.7 Percentage of Participants	50.0 Percentage of Participants	100.0 Percentage of Participants	100.0 Percentage of Participants	83.3 Percentage of Participants	100.0 Percentage of Participants	100.0 Percentage of Participants	43.8 Percentage of Participants

PRIMARY outcome

Timeframe: up to 7 weeks

An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not considered related to the medicinal product. The percentage of participants that were discontinued from the study due to an AE was summarized. Adverse events were summarized by dose taken at the time of the event.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 14.0 mg MK-8892	Placebo-Healthy n=16 Participants Single oral dose of placebo to match MK-8892
Percentage of Participants Who Were Discontinued From the Study Due to an AE- Healthy Participants	0.0 Percentage of Participants	0.0 Percentage of Participants	0.0 Percentage of Participants	0.0 Percentage of Participants	0.0 Percentage of Participants	0.0 Percentage of Participants	0.0 Percentage of Participants	0.0 Percentage of Participants	0.0 Percentage of Participants

PRIMARY outcome

Timeframe: Predose (baseline) and 2, 3, 4, 6, 8, 12, 16 and 24 hours postdose (for each Dosing Period of Each Panel)

Population: Healthy participants (Panels A and B) who were administered study drug in a fasted state, who complied with the protocol sufficiently to ensure that these data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint.

Central diastolic blood pressure measurements were obtained at predose and at 2, 3, 4, 6, 8, 12, 16 and 24 hours postdose via applanation tonometry of the radial artery. The average central diastolic blood pressure over the 24-hour monitoring period was calculated for each dose of each panel by adjusting each time-point by the baseline, aggregating the area under the curve (AUC) by the trapezoidal method and then dividing the AUC by 24 hours. A negative number indicates a decrease.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 14.0 mg MK-8892	Placebo-Healthy n=16 Participants Single oral dose of placebo to match MK-8892
Change in 24-hour Time-weighted Average (TWA0-24hr) for Central Diastolic Blood Pressure (cDBP)- Healthy Participants	-1.83 mm Hg Standard Error 1.71	-2.27 mm Hg Standard Error 1.69	-4.21 mm Hg Standard Error 1.70	-4.25 mm Hg Standard Error 1.71	-6.22 mm Hg Standard Error 1.70	-6.64 mm Hg Standard Error 1.69	-6.94 mm Hg Standard Error 1.69	-8.89 mm Hg Standard Error 1.70	-1.33 mm Hg Standard Error 1.26

PRIMARY outcome

Timeframe: up to 7 weeks

Population: All hypertensive participants (Panel C) who received at least 1 dose of the study drug in a fasted state.

An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized. Adverse events were summarized by dose taken at the time of the event.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=9 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=8 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Percentage of Participants Who Report 1 or More Adverse Events (AEs) - Hypertensive Participants	50.0 Percentage of Participants	33.3 Percentage of Participants	66.7 Percentage of Participants	77.8 Percentage of Participants	75.0 Percentage of Participants	—	—	—	—

PRIMARY outcome

Timeframe: up to 7 weeks

Population: All hypertensive participants (Panel C) who received at least 1 dose of the study drug in a fasted state.

An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The percentage of participants that were discontinued from the study due to an AE was summarized. Adverse events were summarized by dose taken at the time of the event.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=9 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=8 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Percentage of Participants Who Were Discontinued From the Due to an AE - Hypertensive Participants	0.0 Percentage of Participants	0.0 Percentage of Participants	0.0 Percentage of Participants	0.0 Percentage of Participants	0.0 Percentage of Participants	—	—	—	—

PRIMARY outcome

Timeframe: Predose (baseline) and 2, 3, 4, 6, 8, 12, 16 and 24 hours postdose (for each Dosing Period)

Population: Hypertensive participants (Panel C) who were administered study drug in a fasted state, who complied with the protocol sufficiently to ensure that these data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint.

Central diastolic blood pressure measurements were obtained at predose and 2, 3, 4, 6, 8, 12, 16 and 24 hours postdose via applanation tonometry of the radial artery. The average central diastolic blood pressure over the 24-hour monitoring period was calculated for each dose of each panel by adjusting each time-point by the baseline, aggregating the area under the curve (AUC) by the trapezoidal method and then dividing the AUC by 24 hours. A negative number indicates a decrease.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=8 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Change in 24-hour Time-weighted Average (TWA0-24hr) for Central Diastolic Blood Pressure (cDBP) - Hypertensive Participants	-3.56 mm Hg Standard Error 1.87	-4.76 mm Hg Standard Error 1.85	-7.55 mm Hg Standard Error 1.85	-7.86 mm Hg Standard Error 1.59	-1.22 mm Hg Standard Error 1.67	—	—	—	—

SECONDARY outcome

Timeframe: Predose and 2, 3, 4, 6, 8, 12, 16 and 24 hours postdose (for each Dosing Period of Each Panel)

Population: Healthy participants (Panels and B) who were administered study drug in a fasted state, who complied with the protocol sufficiently to ensure that these data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint.

Peripheral diastolic blood pressure was measured using a validated automatic measuring device. The time-weighted average change from baseline was calculated by adjusting each time-point by the baseline, aggregating the area under the curve (AUC) by the trapezoidal method and then dividing the AUC by 24 hours. A negative number indicates a decrease.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 14.0 mg MK-8892	Placebo-Healthy n=16 Participants Single oral dose of placebo to match MK-8892
Change in TWA0-24hrs for Peripheral Diastolic Blood Pressure (pDBP) - Healthy Participants	-4.34 mm Hg Standard Error 1.73	-2.43 mm Hg Standard Error 0.83	-3.69 mm Hg Standard Error 1.10	-4.50 mm Hg Standard Error 1.49	-6.56 mm Hg Standard Error 1.06	-7.04 mm Hg Standard Error 0.99	-7.35 mm Hg Standard Error 0.71	-9.89 mm Hg Standard Error 1.68	-1.67 mm Hg Standard Error 0.82

SECONDARY outcome

Timeframe: Predose (baseline) and every 30 minutes from 0.5-4 hours postdose; hourly from 4-12 hours postdose; every 2 hours from 12-16 hours postdose; and at 24 postdose (for each Dosing Period of Each Panel)

Heart rate was measured predose and every 30 minutes from 0.5-4 hours postdose; hourly from 4-12 hours postdose; every 2 hours from 12-16 hours postdose; and at 24 postdose by a validated automatic measuring device. The time-weighted average change from baseline was calculated by adjusting each time-point by the baseline, aggregating the area under the curve (AUC) by the trapezoidal method and then dividing the AUC by 24 hours. A negative number indicates a decrease.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 14.0 mg MK-8892	Placebo-Healthy n=16 Participants Single oral dose of placebo to match MK-8892
Change in TWA0-24hrs for Heart Rate (HR) - Healthy Participants	0.46 beats per minute (bpm) Standard Error 1.36	5.55 beats per minute (bpm) Standard Error 1.32	4.71 beats per minute (bpm) Standard Error 1.42	7.44 beats per minute (bpm) Standard Error 1.93	9.29 beats per minute (bpm) Standard Error 2.22	8.85 beats per minute (bpm) Standard Error 1.93	10.34 beats per minute (bpm) Standard Error 1.09	16.29 beats per minute (bpm) Standard Error 2.21	2.23 beats per minute (bpm) Standard Error 1.11

SECONDARY outcome

Timeframe: Predose (baseline) and 2, 4, 12, and 24 hours postdose (for each Dosing Period of Each Panel)

AIx was measured by applanation tonometry of the radial artery. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Augmentation index is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. The time-weighted average change from baseline was calculated by adjusting each time-point by the baseline, aggregating the area under the curve (AUC) by the trapezoidal method and then dividing the AUC by 24 hours.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 14.0 mg MK-8892	Placebo-Healthy n=16 Participants Single oral dose of placebo to match MK-8892
Change in TWA0-24hr for Augmentation Index (AIx) - Healthy Participants	-1.73 Percentage Standard Error 2.30	-2.31 Percentage Standard Error 2.32	-2.82 Percentage Standard Error 2.31	-0.26 Percentage Standard Error 2.38	-4.23 Percentage Standard Error 2.29	-3.85 Percentage Standard Error 2.31	-1.84 Percentage Standard Error 2.30	-4.81 Percentage Standard Error 2.32	-0.07 Percentage Standard Error 2.06

SECONDARY outcome

Timeframe: Predose (baseline) and 2, 3, 4, 6, 8, 12, 16 and 24 hours postdose (for each Dosing Period of Each Panel)

Peripheral blood pressure assessments were obtained at predose and 2, 3, 4, 6, 8, 12, 16 and 24 hours postdose by using a validated automatic measuring device. Peripheral diastolic blood pressure was measured a validated automatic measuring device. The time-weighted average change from baseline was calculated by adjusting each time-point by the baseline, aggregating the area under the curve (AUC) by the trapezoidal method and then dividing the AUC by 24 hours. Negative number indicates a decrease.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=8 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Change in TWA0-24hrs for Peripheral Diastolic Blood Pressure (pDBP) - Hypertensive Participants	-3.40 mm Hg Standard Error 1.13	-4.17 mm Hg Standard Error 1.63	-7.29 mm Hg Standard Error 1.40	-9.16 mm Hg Standard Error 1.43	-0.87 mm Hg Standard Error 1.40	—	—	—	—

SECONDARY outcome

Timeframe: Predose and every 30 minutes from 0.5-4 hours postdose; hourly from 4-12 hours postdose; every 2 hours from 12-16 hours postdose; and at 24 postdose (for each Dosing Period of Each Panel)

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=8 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Change in TWA0-24hrs for Heart Rate (HR) - Hypertensive Participants	-0.92 bpm Standard Error 1.59	-0.74 bpm Standard Error 1.88	0.87 bpm Standard Error 1.92	7.68 bpm Standard Error 1.51	-1.46 bpm Standard Error 1.62	—	—	—	—

SECONDARY outcome

Timeframe: Predose to 24 hours Postdose (for each Dosing Period of Each Panel)

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=8 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
TWA0-24hr for Augmentation Index (AIx) - Hypertensive Participants	-2.30 Percentage Standard Error 2.01	-2.57 Percentage Standard Error 2.01	-3.94 Percentage Standard Error 2.01	-5.43 Percentage Standard Error 1.80	-1.65 Percentage Standard Error 1.86	—	—	—	—

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose

Blood samples taken at Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose of each dosing period to determine the AUC0-24hr.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Area Under the Concentration Time-curve From Hour 0 to 24 Hours (AUC0-24hr) of MK-8892 - Healthy Participants	67 nM·hr Geometric Coefficient of Variation 27	128 nM·hr Geometric Coefficient of Variation 32	218 nM·hr Geometric Coefficient of Variation 11	464 nM·hr Geometric Coefficient of Variation 28	694 nM·hr Geometric Coefficient of Variation 14	793 nM·hr Geometric Coefficient of Variation 31	1202 nM·hr Geometric Coefficient of Variation 25	1306 nM·hr Geometric Coefficient of Variation 18	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose of each dosing period to determine the AUC0-last.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Plasma Concentration Time Point (AUC0-last) of MK-8892 - Healthy Participants	103.3 nM·hr Geometric Coefficient of Variation 40.0	216.8 nM·hr Geometric Coefficient of Variation 58.7	368.5 nM·hr Geometric Coefficient of Variation 29.2	724.7 nM·hr Geometric Coefficient of Variation 42.9	1157.6 nM·hr Geometric Coefficient of Variation 26.4	1293.3 nM·hr Geometric Coefficient of Variation 39.4	2286.3 nM·hr Geometric Coefficient of Variation 35.7	2527.7 nM·hr Geometric Coefficient of Variation 25.5	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose of each dosing period to determine the AUC0-inf.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Area Under the Concentration Time-curve From Hour 0 to Infinity (AUC0-inf) of MK-8892 - Healthy Participants	113 nM·hr Geometric Coefficient of Variation 37	232 nM·hr Geometric Coefficient of Variation 63	391 nM·hr Geometric Coefficient of Variation 34	757 nM·hr Geometric Coefficient of Variation 50	1195 nM·hr Geometric Coefficient of Variation 30	1342 nM·hr Geometric Coefficient of Variation 41	2443 nM·hr Geometric Coefficient of Variation 39	2702 nM·hr Geometric Coefficient of Variation 31	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose of each dosing period to determine the Cmax.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Maximum Concentration (Cmax) of MK-8892 - Healthy Participants	4.8 nM Geometric Coefficient of Variation 32	8.5 nM Geometric Coefficient of Variation 23	17.9 nM Geometric Coefficient of Variation 19	35.6 nM Geometric Coefficient of Variation 26	49.0 nM Geometric Coefficient of Variation 21	52.8 nM Geometric Coefficient of Variation 38	72.8 nM Geometric Coefficient of Variation 23	87.3 nM Geometric Coefficient of Variation 16	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose of each dosing period to determine the Tmax.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Time to Cmax (Tmax) of MK-8892 - Healthy Participants	4 hours Interval 2.0 to 6.0	4 hours Interval 1.0 to 6.0	4 hours Interval 1.0 to 6.0	4 hours Interval 1.0 to 6.0	4 hours Interval 2.0 to 6.0	5 hours Interval 4.0 to 8.0	4 hours Interval 4.0 to 8.0	2 hours Interval 1.0 to 8.0	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose of each dosing period to determine the t1/2.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Apparent Terminal Half-life (t1/2) of MK-8892 - Healthy Participants	17.9 Hours Geometric Coefficient of Variation 28	20.6 Hours Geometric Coefficient of Variation 40	20.1 Hours Geometric Coefficient of Variation 44	17.7 Hours Geometric Coefficient of Variation 43	15.6 Hours Geometric Coefficient of Variation 45	20.9 Hours Geometric Coefficient of Variation 28	23.7 Hours Geometric Coefficient of Variation 23	21.1 Hours Geometric Coefficient of Variation 41	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose of each dosing period to determine the AUC0-24hr.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Area Under the Concentration Time-curve From Hour 0 to 24 Hours (AUC0-24hr) of MK-8892 - Hypertensive Participants	79 nM·hr Geometric Coefficient of Variation 27	158 nM·hr Geometric Coefficient of Variation 14	285 nM·hr Geometric Coefficient of Variation 17	806 nM·hr Geometric Coefficient of Variation 24	714 nM·hr Geometric Coefficient of Variation 22	—	—	—	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose

Population: Hypertensive participants (Panel C) who complied with the protocol sufficiently to ensure that these data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint.

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose of each dosing period to determine the AUC0-last.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Plasma Concentration Time Point (AUC0-last) of MK-8892 - Hypertensive Participants	150.2 nM·hr Geometric Coefficient of Variation 45.9	317.3 nM·hr Geometric Coefficient of Variation 25.9	522.3 nM·hr Geometric Coefficient of Variation 24.0	1700.2 nM·hr Geometric Coefficient of Variation 38.5	1538.8 nM·hr Geometric Coefficient of Variation 23.5	—	—	—	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose of each dosing period to determine the AUC0-inf.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Area Under the Concentration Time-curve From Hour 0 to Infinity (AUC0-inf) of MK-8892- Hypertensive Participants	164.0 nM·hr Geometric Coefficient of Variation 53.0	346.0 nM·hr Geometric Coefficient of Variation 32.0	557.0 nM·hr Geometric Coefficient of Variation 28.0	1947.0 nM·hr Geometric Coefficient of Variation 48.0	1760.0 nM·hr Geometric Coefficient of Variation 38.0	—	—	—	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose of each dosing period to determine the Cmax.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Maximum Concentration (Cmax) of MK-8892- Hypertensive Participants	4.9 nM Geometric Coefficient of Variation 21.0	9.8 nM Geometric Coefficient of Variation 13.0	17.6 nM Geometric Coefficient of Variation 30.0	48.9 nM Geometric Coefficient of Variation 15.0	47.1 nM Geometric Coefficient of Variation 33.0	—	—	—	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose of each dosing period to determine the Tmax.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Time to Cmax (Tmax) of MK-8892- Hypertensive Participants	3 Hours Interval 1.0 to 6.0	4 Hours Interval 2.0 to 8.0	6 Hours Interval 4.0 to 12.0	4 Hours Interval 2.0 to 12.0	4 Hours Interval 4.0 to 8.0	—	—	—	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose of each dosing period to determine the t1/2.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 Participants Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy n=5 Participants Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Apparent Terminal Half-life (t1/2) of MK-8892- Hypertensive Participants	23.5 Hours Geometric Coefficient of Variation 30	24.5 Hours Geometric Coefficient of Variation 28	21.6 Hours Geometric Coefficient of Variation 34	28.8 Hours Geometric Coefficient of Variation 49	26.3 Hours Geometric Coefficient of Variation 57	—	—	—	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose

Population: Healthy participants (Panel A) who were administered 2.0 mg MK-8892 in both fasted and fed state, who complied with the protocol sufficiently to ensure that these data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint.

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose of each dosing period to determine the AUC0-24hr. A mixed effects model with Cohort (Healthy or hypertensive) as a fixed term, participant as a random effect was used for summary data. For participants that participated in Period 5, study drug was administered after a standard high-fat breakfast provided approximately 30 minutes prior to dosing. The meal was consumed in a 20-minute period with start and stop times being recorded. Participants were administered a single dose of MK-8892 or matching placebo Within 10 minutes of completing the meal.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Area Under the Concentration Time-curve From Hour 0 to 24 Hours (AUC0-24hr) of 2.0 mg MK-8892-Healthy Participants-Fasted/Fed	218.2 nM·hr Interval 199.3 to 238.9	278.2 nM·hr Interval 241.5 to 320.4	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose of each dosing period to determine the AUC0-last. A mixed effects model with Cohort (Healthy or hypertensive) as a fixed term, participant as a random effect was used for summary data. For participants that participated in Period 5, study drug was administered after a standard high-fat breakfast provided approximately 30 minutes prior to dosing. The meal was consumed in a 20-minute period with start and stop times being recorded. Participants were administered a single dose of MK-8892 or matching placebo Within 10 minutes of completing the meal.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Plasma Concentration Time Point (AUC0-last) of 2.0 mg MK-8892 - Healthy Participants-Fasted/Fed	368.5 nM·hr Geometric Coefficient of Variation 29.2	494.6 nM·hr Geometric Coefficient of Variation 29.2	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose of each dosing period to determine the AUC0-inf. A mixed effects model with Cohort (Healthy or hypertensive) as a fixed term, participant as a random effect was used for summary data. For participants that participated in Period 5, study drug was administered after a standard high-fat breakfast provided approximately 30 minutes prior to dosing. The meal was consumed in a 20-minute period with start and stop times being recorded. Participants were administered a single dose of MK-8892 or matching placebo Within 10 minutes of completing the meal.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Area Under the Concentration Time-curve From Hour 0 to Infinity (AUC0-inf) of 2.0 mg MK-8892 - Healthy Participants-Fasted/Fed	390.0 nM·hr Interval 298.7 to 509.1	518.5 nM·hr Interval 400.6 to 671.1	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose of each dosing period to determine the Cmax. A mixed effects model with Cohort (Healthy or hypertensive) as a fixed term, participant as a random effect was used for summary data. For participants that participated in Period 5, study drug was administered after a standard high-fat breakfast provided approximately 30 minutes prior to dosing. The meal was consumed in a 20-minute period with start and stop times being recorded. Participants were administered a single dose of MK-8892 or matching placebo Within 10 minutes of completing the meal.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Maximum Concentration (Cmax) of 2.0 mg MK-8892 - Healthy Participants- Fasted/Fed	17.9 nM Interval 15.3 to 20.9	20.5 nM Interval 17.8 to 23.6	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose

Blood samples taken at Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose of each dosing period to determine the t1/2.A mixed effects model with Cohort (Healthy or hypertensive) as a fixed term, participant as a random effect was used for summary data. For participants that participated in Period 5, study drug was administered after a standard high-fat breakfast provided approximately 30 minutes prior to dosing. The meal was consumed in a 20-minute period with start and stop times being recorded. Participants were administered a single dose of MK-8892 or matching placebo Within 10 minutes of completing the meal.

Outcome measures

Outcome measures
Measure	0.5 mg MK-8892-Healthy n=6 Participants Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 Participants Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) Single oral dose of 2.0 mg MK-8892	4.0 mg MK-8892-Healthy Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy Single oral dose of 14.0 mg MK-8892	Placebo-Healthy Single oral dose of placebo to match MK-8892
Apparent Terminal Half-life (t1/2) of 2.0 mg MK-8892 - Healthy Participants -Fasted/Fed	20.1 Hours Interval 14.3 to 28.5	20.5 Hours Interval 17.3 to 24.2	—	—	—	—	—	—	—

Adverse Events

0.5 mg MK-8892-Healthy

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

1.0 mg MK-8892-Healthy

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

2.0 mg MK-8892-Healthy (Pooled)

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

4.0 mg MK-8892-Healthy

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

6.0 mg MK-8892-Healthy

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

9.0 mg MK-8892-Healthy

Serious events: 0 serious events

Other events: 5 other events

Deaths: 0 deaths

12.0 mg MK-8892-Healthy

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

14.0 mg MK-8892-Healthy

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Placebo-Healthy

Serious events: 0 serious events

Other events: 7 other events

Deaths: 0 deaths

0.5 mg MK-8892-Hypertensive

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

1.0 mg MK-8892-Hypertensive

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

2.0 mg MK-8892-Hypertensive

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

6.0 mg MK-8892-Hypertensive

Serious events: 0 serious events

Other events: 7 other events

Deaths: 0 deaths

Placebo-Hypertensive

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	0.5 mg MK-8892-Healthy n=6 participants at risk Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Healthy n=6 participants at risk Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Healthy (Pooled) n=6 participants at risk Single oral dose of 2.0 mg MK-8892.	4.0 mg MK-8892-Healthy n=6 participants at risk Single oral dose of 4.0 mg MK-8892	6.0 mg MK-8892-Healthy n=6 participants at risk Single oral dose of 6.0 mg MK-8892	9.0 mg MK-8892-Healthy n=6 participants at risk Single oral dose of 9.0 mg MK-8892	12.0 mg MK-8892-Healthy n=6 participants at risk Single oral dose of 12.0 mg MK-8892	14.0 mg MK-8892-Healthy n=6 participants at risk Single oral dose of 14.0 mg MK-8892	Placebo-Healthy n=16 participants at risk Single oral dose of placebo to match MK-8892	0.5 mg MK-8892-Hypertensive n=6 participants at risk Single oral dose of 0.5 mg MK-8892	1.0 mg MK-8892-Hypertensive n=6 participants at risk Single oral dose of 1.0 mg MK-8892	2.0 mg MK-8892-Hypertensive n=6 participants at risk Single oral dose of 2.0 mg MK-8892	6.0 mg MK-8892-Hypertensive n=9 participants at risk Single oral dose of 6.0 mg MK-8892. Includes rechallenge	Placebo-Hypertensive n=8 participants at risk Single oral dose of placebo to match MK-8892
Investigations Blood pressure systolic increased	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	11.1% 1/9 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	12.5% 1/8 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 2 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Investigations Blood pressure systolic decreased	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	6.2% 1/16 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 2 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	22.2% 2/9 • Number of events 3 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Injury, poisoning and procedural complications Upper limb wound	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Cardiac disorders Palpitations	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	33.3% 2/6 • Number of events 2 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	11.1% 1/9 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Cardiac disorders Postural orthostatic tachycardia syndrome	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 2 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Ear and labyrinth disorders Tinnitus	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	11.1% 1/9 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Gastrointestinal disorders Abdominal distension	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Gastrointestinal disorders Abdominal pain	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Gastrointestinal disorders Change of bowel habit	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	12.5% 1/8 • Number of events 2 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Gastrointestinal disorders Constipation	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Gastrointestinal disorders Dyspepsia	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Gastrointestinal disorders Loose stools	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	6.2% 1/16 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	11.1% 1/9 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Gastrointestinal disorders Nausea	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	11.1% 1/9 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	25.0% 2/8 • Number of events 2 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Gastrointestinal disorders Vomiting	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	11.1% 1/9 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
General disorders Chest pain	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	12.5% 1/8 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
General disorders Cyst	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
General disorders Fatigue	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 2 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	18.8% 3/16 • Number of events 4 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	12.5% 1/8 • Number of events 2 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
General disorders Feeling hot	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	11.1% 1/9 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
General disorders Oedema peripheral	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	11.1% 1/9 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Infections and infestations Common cold	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	12.5% 2/16 • Number of events 2 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Infections and infestations Oral herpes	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	6.2% 1/16 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Injury, poisoning and procedural complications Lower limb wound	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Injury, poisoning and procedural complications Open wound	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	6.2% 1/16 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Musculoskeletal and connective tissue disorders Back pain (with radiation)	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	11.1% 1/9 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	11.1% 1/9 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Musculoskeletal and connective tissue disorders Pain in arm	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	12.5% 1/8 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Musculoskeletal and connective tissue disorders Shoulder pain	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	12.5% 1/8 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Nervous system disorders Dizziness	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Nervous system disorders Dizziness postural	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	11.1% 1/9 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Nervous system disorders Headache	33.3% 2/6 • Number of events 2 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	50.0% 3/6 • Number of events 3 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 2 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	83.3% 5/6 • Number of events 6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	66.7% 4/6 • Number of events 4 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	50.0% 3/6 • Number of events 4 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	100.0% 6/6 • Number of events 9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	66.7% 4/6 • Number of events 6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 2 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	33.3% 2/6 • Number of events 2 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	55.6% 5/9 • Number of events 6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	50.0% 4/8 • Number of events 7 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Nervous system disorders Presyncope	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	11.1% 1/9 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Renal and urinary disorders Polyuria	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Renal and urinary disorders Urine odour abnormal	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	11.1% 1/9 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Respiratory, thoracic and mediastinal disorders Bronchial hyperreactivity	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	6.2% 1/16 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	11.1% 1/9 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Skin and subcutaneous tissue disorders Eczema	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	12.5% 1/8 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Skin and subcutaneous tissue disorders Skin irritation	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	16.7% 1/6 • Number of events 2 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	6.2% 1/16 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Skin and subcutaneous tissue disorders Urtication	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	6.2% 1/16 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Vascular disorders Haematoma	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	6.2% 1/16 • Number of events 1 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.
Vascular disorders Orthostatic hypotension	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	50.0% 3/6 • Number of events 3 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/16 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/6 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/9 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.	0.00% 0/8 • up to 7 weeks All participants who received at least 1 dose of the study drug. Adverse events are reported by dose taken at time of event and not by panel or sequence. As pre-specified in the protocol, safety data were pooled for the MK 8892 2.0 mg fed and fasted arms only and were not planned to be provided separately.

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme Corp.

Phone: 1-800-672-6372

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.
Publication restrictions are in place

Restriction type: OTHER